Billiontoone Inc (BLLN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$113.89+3.11%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · BLLN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 269.6% |
| Our one-year growth estimate | diamond | 37.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 232.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers
BLLN — earnings in line
Dated 2026-08-05
Results of Operations and Financial Condition. On August 5, 2026 , BillionToOne, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be in…
Why it matters: The range calls for 48% to 52% growth. Results below its pace could put that goal at risk.
Worry ifThe next report keeps full-year revenue guidance at $450M–$465M or raises it.
Less concerning ifThe company cuts guidance below $450M, or reports 2026 revenue below the range.
Why it matters: The panel became available on August 17. Paid test use would show whether the launch adds sales.
Supportive ifA company update reports paid tests using the 130-gene panel and gives test volume or revenue.
Worry ifA company update reports the launch was delayed, or reports no paid tests using the panel.
Why it matters: Q2 revenue grew through more tests and a higher average price. A drop in either could slow sales growth.
Worry ifQ3 tests delivered grow year over year and average price per test is at least $551.
Less concerning ifQ3 tests delivered fall year over year, or average price per test drops below $551.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$224 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $797 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,081 loss on $10,000 · 50.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.